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Introduction. Late onset depressive symptoms (LODSs) frequently occur in elderly with cerebral small vessel disease (SVD). SVD
cannot fully explain LODS; a contributing factor could be amygdala volume. We investigated the relation between amygdala
volume and LODS, independent of SVD in 503 participants with symptomatic cerebral SVD. Methods. Patients underwent
FLAIR and T1 scanning. Depressive symptoms were assessed with structured questionnaires; amygdala and WML were manually
segmented. The relation between amygdala volume and LODS/EODS was investigated and adjusted for age, sex, intracranial
volume, and SVD. Results. Patients with LODS had a significantly lower left amygdala volume than those without (P = 0.02),
independent of SVD. Each decrease of total amygdala volume (by mL) was related to an increased risk of LODS (OR = 1.77; 95%
CI 1.02–3.08; P = 0.04). Conclusion. Lower left amygdala volume is associated with LODS, independent of SVD. This may suggest
diﬀerential mechanisms, in which individuals with a small amygdala might be vulnerable to develop LODS.
1. Introduction
A first depressive episode at older age is defined as late onset
depressive symptoms (LODSs). LODSs are usually defined
by their occurrence after the age of 60 years, while early onset
depressive symptoms (EODSs) appear before. The preva-
lence of LODS and EODS ranges from 10% to 32% [1–4]
in the elderly population. Patients with EODS show a higher
rate of family history of depression than patients with LODS;
genetic factors appear to be important. While psychological
and genetic factors presumably play an important role in
EODS [5], there are probably other nongenetic factors that
play a role in LODS [5, 6] such as structural changes in the
brain [7, 8].
Population-based neuroimaging studies suggest a possible
role for frequently occurring white matter lesions (WMLs)
in the etiology of LODS [9–12]. Their dominant view is that
WMLs disrupt white matter tracts connecting cortical and
subcortical structures (e.g., frontostriatal circuits), which re-
sult in LODS [13, 14].
As WML are part of the cerebral small vessel disease
(SVD) spectrum, also including lacunar infarcts, it could be
that the association between WML and LODS is driven by
lacunar infarcts as they reflect more severe structural damage
thanWML. In addition, SVDmight not fully explain the pre-
sence of depressive symptoms in elderly as there are patients
with LODS without SVD.
A functional or structural change in the amygdala may
explain the residual depressive symptoms as the amygdala is
involved in mood regulation, and structural MRI studies
showed a lower amygdala volume in patients with both
LODS and EODS than in healthy controls [15–18]. However,
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these studies did not adjust for the possible confounding role
of SVD. Conversely, none of the population-based studies
on SVD and LODS took amygdala volume into account. We
therefore wanted to investigate the relation between amyg-
dala volume and the presence of depressive symptoms in pa-
tients with SVD, with adjustment for degree of SVD.
2. Patients and Methods
2.1. Study Population. The Radboud University Nijmegen
Diﬀusion tensor and Magnetic resonance imaging Cohort
(RUN DMC) study is a prospective cohort study that investi-
gates the risk factors and cognitive, motor, andmood conseq-
uences of functional and structural brain changes among
elderly with cerebral SVD.
Cerebral SVD is characterised on neuroimaging by either
WML or lacunar infarcts. Symptoms include acute symp-
toms, such as transient ischaemic attacks (TIAs) or lacunar
syndromes, or subacute manifestations, such as cognitive,
motor (gait) and/or mood disturbances [19]. As the onset
of cerebral SVD is often insidious, clinically heterogeneous,
and typically with mild symptoms, it has been suggested that
the selection of subjects with cerebral SVD in clinical stud-
ies should be based on the more consistent brain imaging
features [20].
Accordingly, in 2006, consecutive patients who visited
the department of neurology, between October 2002 and
November 2006, were selected for participation. Inclusion
criteria were (a) age between 50 and 85 years; (b) cerebral
SVD on neuroimaging (WML and/or lacunar infarcts). Sub-
sequently the above-mentioned acute or subacute clinical
symptoms of SVD were assessed by standardized structured
assessments. Patients who were eligible because of a lacunar
syndrome were included only >6 months after the event to
avoid acute eﬀects on the outcomes.
Exclusion criteria were (a) dementia and (b) parkin-
son(ism) according to the international diagnostic criteria
[21–23]; (c) life expectancy of less than six months; (d)
intracranial space occupying lesion; (e) (psychiatric) disease
interfering with cognitive testing or followup; (f) recent or
current use of acetylcholine-esterase inhibitors, neuroleptic
agents, L-dopa, or dopa-a(nta)gonists; (g) WML mimics
(e.g., multiple sclerosis and irradiation induced gliosis); (h)
prominent visual or hearing impairment; (i) language bar-
rier; (j) MRI contraindications or known claustrophobia.
Patients were selected in a three-step approach. After
reviewing medical records 1004 individuals were invited by
letter, 727 were eligible after contact by phone, and 525
agreed to participate. In 22 subjects exclusion criteria were
found during their visit to our research centre (14 with un-
expected claustrophobia, 1 died before MRI scanning, 1 was
diagnosed with multiple sclerosis, in 1 there was a language
barrier, 1 subject fulfilled the criteria for Parkinson’s disease,
and 4 met the dementia criteria), yielding a response of
71.3% (503/705). From these 503 individuals one group had
symptoms of TIA or lacunar syndrome (n = 219), and the
remaining (n = 284) had cognitive disturbances, motor di-
sturbances, depressive symptoms, or a combination thereof.
All participants signed an informed consent form. TheMedi-
cal Review Ethics Committee region Arnhem-Nijmegen ap-
proved the study.
2.2. MRI Acquisition. Imaging was performed on a 1,5 Tesla
MRI scanner (Magnetom, Sonata; Siemens Medical Solu-
tions, Erlangen, Germany). The protocol included 3D
MPRAGE imaging (TR/TE/TI 2250/3.68/850ms; flip
angle15◦; voxel size 1.0× 1.0× 1.0mm) and fluid attenuated
inversion recovery (FLAIR) sequences (TR/TE/TI 9000/84/
2200ms; voxel size 1.0× 1.2× 5.0mm, with an interslice gap
of 1.0mm). All scans were performed on the same scanner.
2.3. Amygdala Volumetry. One investigator, blinded to the
clinical and other imaging data (IvU), performed manual
segmentation of the amygdala, using the interactive soft-
ware program “ITK-SNAP” [24] (http://www.itksnap.org/).
Briefly, this program allowed simultaneous viewing of
volumes in coronal sagittal and transversal view, thereby
permitting a neat handling of anatomical borders while
segmenting the regions of interest. Left and right amyg-
dalae were manually segmented in the coronal plane, from
posterior to anterior. Next, segmentations were reviewed
in the sagittal plane, because then boundaries were better
visualized [25–27]. Segmentation was performed according
to previously published protocols [27, 28], and the correct
segmentation of anatomical boundaries was verified with the
aid of neuroanatomical atlases [28, 29]. In short, the first slice
of the amygdala, the posterior border, was identified superior
to the hippocampus at the point where the white matter
first starts to appear superior to the alveus and laterally to
the hippocampal head. The anterior border of the amygdala
was defined at the level where the amygdala no longer has
an ovoid shape. The medial border is marked by the medial
margin of the temporal lobe, which borders Cerebral Spinal
Fluid (CSF). The lateral/inferior border is the surrounding
white matter and the inferior horn of the lateral ventricle.
The amygdala and hippocampus were carefully separated on
the sagittal view, moving from the medial to the lateral side
of the brain.
Segmentations were done in a standardized way by rating
the left amygdala first for half of the patients and the right
amygdala first for the other half. Volume was calculated for
the left and right amygdala separately by summing all seg-
mented areas, multiplied by slice thickness. Intrarater on a
random sample yielded an intraclass correlation coeﬃcient
for both left and right amygdalae of 0.8.
2.4. WML Volumetry and Lacunar Infarcts. White matter
signal hyperintensities on FLAIR scans, which were not,
or only faintly hypointense on T1-weighted images, were
considered WML, except for gliosis surrounding infarcts.
WMLs were manually segmented on transversal FLAIR
images, by 2 trained raters, (IvU, LvO), blinded for all
clinical data and amygdala volumes. Total WML volume
was calculated in the same fashion as for both amydalae.
Inter-rater variability for total WML volume was determined
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on a random sample of ten percent yielded an intra-class
correlation coeﬃcient of 0.99.
Lacunar infarcts were defined as areas with a diameter
>2mm and <15mm with low signal intensity on FLAIR and
T1, ruling out enlarged perivascular spaces and infraputami-
nal pseudolacunes [30]. Evaluation of infarcts was performed
by one person with a good intra-rater variability with a
weighted kappa of 0.80. In ten percent of the scans inter-rater
variability was calculated with a weighted kappa of 0.88.
2.5. Brain Volumetry. Gray (GM), white matter (WM) tissue,
and CSF probability maps were computed using SPM5
routines (Wellcome Department of Cognitive Neurology,
University College London, UK). Total GM, WM, and CSF
volumes were calculated by summing all voxel volumes that
had a P > 0.5 for belonging to the tissue class. Intracranial
volume (ICV) was taken as the sum of total GM, WM, and
CSF.
2.6. Assessment of Depressive Symptoms. Depressive symp-
toms were assessed with the Center of Epidemiologic Studies
Depression Scale (CES-D) [31]. Depressive symptoms were
considered present in patients with a CES-D score ≥16
and/or current use of antidepressive medication, taken for
depression, irrespective of their actual CES-D score, because
depressive symptoms were considered to be the indication
for the medication prescription.
In addition, all patients were asked about their history
of depressive episodes. If depressive episodes had occurred,
the patients were asked for the age of onset and whether
the episodes had prompted them to seek medical advice. A
history of depression was considered present if depressive
episodes in the past had required attention of a general prac-
titioner, psychologist, or psychiatrist [4].
According to the literature we used the age of 60 years as
cut-oﬀ point to distinguish between LODS and EODS [4].
Patients at the age or older than 60 years with a CES-D ≥
16 and/or current use of antidepressive medication, taken for
depression, without a history of depressive episodes before or
at the age of 60, were classified as having LODS. Individuals
with a CESD < 16, without a history of depressive symptoms
and without the current use of antidepressive medication,
formed the reference group. All others fulfilled the criteria
for EODS (first depressive episode <60 years).
2.7. Statistical Analysis. We compared the amygdala and
WML volumes (overall, left, right) between the EODS and
LODS group with the reference using ANCOVA. Adjust-
ments for age, sex, ICV, WML (or amygdala volume with
WML being dependent variable) and presence of lacunar
infarcts were made.
The risk of LODS and EODS per milliliter increases
in amygdala volume, WML volume, and presence (yes/no)
of lacunar infarcts was calculated (expressed as the odds
ratio (OR) with a 95% confidence interval; 95% CI) by
means of age, sex, ICV, adjusted logistic regression analysis
with additional adjustment for the appropriate structural
MRI measures (WML volume, amygdala volume, or lacunar
infarcts). All data were analyzed using SPSS statistical
software, version 16.0. P values < 0.05 were considered
statistical significant.
3. Results
Of the 503 patients one was excluded because of an automatic
segmentation problem that could not be solved manually.
Two patients did not complete the CES-D questionnaire and
of two patients the history of depression was not known.
There were 101 individuals with LODS (20.3%) and 108 with
EODS (21.7%); the reference group comprised 289 persons
(58.0%).
Demographic and neuroimaging characteristics of 498
patients are shown in Table 1.
Mean age of the population was 65.6 years (SD 8.8), and
56.4% were male. Mean age of the LODS group was 71.4
years and of the EODS group 59.1 years. Mean age of onset
of EODS was 45.1 years (SD 10.9).
Total amygdala volume was 3.4mL (SD 0.5), and mean
volume of left amygdala was 1.8mL (SD 0.3) and diﬀered sig-
nificantly (P < 0.001), from the right amygdala 1.6 mL (SD
0.3). Amygdala volume decreased significantly with age (β =
−0.339; P < 0.001), and women had smaller amygdala
(3.2mL; SD 0.4) than men (3.5mL; SD 0.5; P < 0.001).
Table 2 shows that patients with LODS had a higher
WML volume (21.8mL; SD 20.2) than the reference group
(14.7mL; SD 18.0), although not significant (P = 0.06).
Independent of SVD, patients with LODS had a significant
lower left amygdala volume (1.6mL; SD 0.3; P = 0.017) than
the reference group (1.8mL; 0.28); this diﬀerence was not
found for the right amygdala (1.5mL; SD 0.3, P = 0.432).
Patients with EODS did not diﬀer from the reference
group with respect to WML volume, amygdala volume, and
the proportion of lacunar infarcts. We found no significant
diﬀerences between left, right, and total amygdala volume,
WML volume, and presence of lacunar infarcts between
patients with LODS and EODS.
Table 3 shows the risk of LODS and EODS and per mL
decrease in total, left, and right amygdala volume, WML
volume (mL), and presence of lacunar infarcts. Each decrease
of both total and left amygdala volume (mL) showed a
significant increased risk of the presence of LODS (OR =
1.77; 95CI 1.02–3.08; P = 0.04, in total amygdala volume
and OR 2.92; 95CI 1.22–7.01; P = 0.02 in left amygdala
volume), independent of SVD. In addition, there was a nearly
significant (P = 0.08) increased risk for LODS per increase
of WML volume. This was not found for EODS and decrease
of amygdala volume (OR = 0.95; 95CI 0.56–1.61; P = 0.86)
per increase of WML volume, or presence of lacunar infarcts.
4. Discussion
In this study of 498 elderly patients with cerebral SVD, left
amygdala volumewas related to LODS, independent ofWML
volume and the presence of lacunar infarcts; this was not
found for EODS and amygdala volume (left, right nor total).
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Table 1: Baseline Characteristics of patients with Late Onset Depressive Symptoms (LODSs), Early Onset Depressive Symptoms (EODSs),
and patients without depressive symptoms.
Depressive symptoms Late onset Early onset Reference Overall
(n = 101)
(20.3%)
(n = 108)
(21.7%)
(n = 289 )
(58.0%)
(n = 498)
(100%)
Age yrs 71.4 (6.0) 59.1 (6.2) 65.9 (9.0) 65.6 (8.8)
Sex (male/female) 47/54 60/48 174/115 281/217
MSSE 27.4 (1.7) 28.4 (1.5) 28.3 (1.6) 28.1 (1.6)
Education (>primary school (%)) 77.2% 95.4% 93.4% 90.6%
Mean CES-D 21.0 (8.0) 16.9 (11.0) 7.7 (5.0) 12.4 (9.3)
WM volume 438.4 (57.1) 484.7 (62.9) 465.3 (68.8) 464.1 (66.9)
GM volume 597.4 (66.7) 649.8 (60.5) 632.3 (65.8) 629.0 (67.1)
ICV
1660.8
(156.1)
1659.9
(146.5)
1687.9
(159.4)
1676.3
(156.3)
Median WML volume 16.8 4.5 8.0 8.0
Number of lacunar infarcts 40 (39.6%) 30 (27.8%) 101 (34.9%) 171 (34.3%)
Use of antidepressive medication 30 (29.7%) 30 (27.8%) 0 (0%) 60 (12.0%)
Number represent mean (SD) or number.
MMSE: Mini Mental State Examination; CES-D: Center for Epidemiological Studies Depression Scale; WM: white matter; GM: gray matter; ICV: intracranial
volume; WML: white matter lesions.
Table 2: Adjusted mean amygdala volume, White Matter Lesions (WMLs) volume, and lacunar infarcts in patients with Late Onset De-
pressive Symptoms (LODSs), Early Onset Depressive Symptoms (EODSs), and patients without depressive symptoms.
Patients with LODS
(n = 101) P-value
† Patients with EODS
(n = 108) P-value
† Reference group
(n = 289)
Total amygdala volume (mL)∗ 3.2 (0.5) 0.05 3.5 (0.5) 0.82 3.4 (0.5)
Left amygdala (mL)∗ 1.6 (0.3) 0.02 1.8 (0.3) 0.71 1.8 (0.28)
Right amygdala (mL)∗ 1.5 (0.3) 0.43 1.7 (0.3) 0.90 1.6 (0.28)
WML volume (mL)∗∗ 21.8 (20.2) 0.06 9.5 (13.8) 0.94 14.7 (18.0)
Lacunar infarcts (%)∗∗∗ 32.9% 0.42 35.8% 0.47 32.0%
Number represent mean (SD) or number.
Data is shown of the comparison of LODS/EODS versus the reference group, ∗adjusted for age, sex, ICV, WML volume, and presence of lacunar infarcts,
∗∗adjusted for age, sex, ICV, presence of lacunar infarcts and amygdala volume, ∗∗∗adjusted for age, sex, ICV, WML and amygdala volume, †compared with
the reference group.
Before conclusions can be drawn, there are some metho-
dological issues that need to be addressed. The proportion of
patients with depressive symptoms in our study is relatively
high (42%) for LODS and EODS together. In other studies
the proportion of patients with depressive symptoms varies
between 9.6%–32% [1–4, 32]. A possible explanation for
our relatively high proportion of patients with depressive
symptoms could be the fact that we purposely included pa-
tients on the basis of presence of SVD; consequently the
median degree of WML volume in our study is higher than
in population-based studies [33]. As these lesions are relat-
ed to LODS it seems reasonable to expect a concomitant
increased presence of depressive symptoms. Our finding
of the (borderline significant) association between WML
volume and LODS is in line with findings from these popu-
lation-based studies [1, 4, 34]. Another explanation is that
we classified patients as suﬀering from depressive symptoms
once they had had a depressive episode in their medical
history or when they used antidepressive drugs at baseline
examination (while previous studies usually did not assess
detailed information on the use of medication) [35]. The
third explanation could be that we included patients with a
history of lacunar stroke and transient ischaemic attacks. It
is known that in this population the prevalence of depressive
symptoms is higher compared to the general population
[36].
To elucidate the etiological mechanisms of LODS its cur-
rent widely used definition suﬀers from a conceptual pro-
blem, due to the fact that age during the first depressive
episode determines the classification. It could very well be
that recovery after EODS occurs while depressive symptoms
develop again after sixty years of age. Despite the fact that
these patients still fulfil the definition of EODS because of
their history, they may have developed their LODS on the
basis of another underlying pathology including SVD. This
could have led to overrepresentation of WML among the
EODS group.
There is a conceptual problem with LODS and EODS.
By definition the EODS sample included many subjects with
major depression. All had consulted a doctor or were at one
Journal of Aging Research 5
Table 3: The risk of LODS and EODS per decrease in amygdala volume, white matter lesion (WML), volume and lacunar infarcts.
Patients with LODS (n = 101) Patients with EODS (n = 108)
OR 95% CI OR 95% CI
Total amygdala volume∗ 1.77 1.02–3.08† 0.95 0.56–1.61
Left amygdala volume∗ 2.92 1.22–7.01† 0.98 0.41–2.30
Right amygdala volume∗ 1.53 0.59– 4.03 0.85 0.34–2.14
WML volume∗∗ 0.99 0.97–1.00 1.01 0.99–1.03
Lacunar infarcts∗∗∗ 1.32 0.78–2.23 0.80 0.46–1.39
Number represent odds ratio (OR), 95% confidence interval (CI), ∗adjusted for age, sex, WML, ICV volume, and presence of lacunar infarcts, ∗∗adjusted for
age, sex, total amygdala volume, ICV, and presence of lacunar infarcts, ∗∗∗adjusted for age, sex, ICV, WML, and amygdala volume, †P < 0.05.
time treated with antidepressants. By contrast, the LODS
sample was defined primarily by the CES-D score (and/or
current antidepressant use). Some may have had major de-
pression and some minor depression. These potential dif-
ferences may aﬀect results both ways.
Another limitation is the cross-sectional nature of our
study, which prevents us from proving causality. The RUN
DMC study has a longitudinal design, and followup is already
planned to evaluate the eﬀect of brain changes on depressive
symptoms [37].
Strengths of our study include its design of a homoge-
neous population that covers the whole spectrum of cerebral
SVD, its size and high response rate of over 70%, and the
use of a single expert who segmented the amygdala, blinded
to clinical information. Particularly the definition of the
anatomic boundaries of the amygdala is a notorious pro-
blem in amygdala segmentation. Our use of one single, expe-
rienced rater minimized the eﬀect of diﬀerential segmen-
tation between several raters thereby limiting the eﬀect mis-
classification. Our results are in line with those from meta-
analyses on amygdala volume in nonclinical samples that
found a mean volume of both left and right amygdala in 39
studies of 1.7 mL, with a range from 1.0 to 3.9mL [28].
Although the amygdala is critical to the interpretation
of emotion [16, 17] and implicated in mood disorders,
volumetric studies of the amygdala in patients with mood
disorders have provided inconsistent results [18]. Studies of
chronic or recurrent depressive patients have found identical
[38, 39], smaller [40–42] but also larger [43] amygdala
volumes compared to controls. Postmortem studies showed
a smaller amygdala in depressed patients compared to con-
trols, probably due to fewer glial cells [15].
Our data showed a significant relationship with LODS
and left amygdala volume; we did not find this relation with
the volume of the right amygdala. This is concordant with
previous neuroimaging and postmortem studies that have
reported left lateralized atrophy in the prefrontal cortex and
amygdala in mood disorders [15, 41, 44, 45]; however pre-
vious results are inconclusive as others also report on an as-
sociation between a decrease in right amygdala volume and
mood [40]. In addition some functional imaging studies have
shown lateralization, with activation of the left amygdala, in
relation to emotion and emotional information processing
[46, 47].
A possible explanation for a smaller amygdala in patients
with LODS could be the coexistent SVD, abnormalities in
blood flow, metabolism, and neurotransmitter receptors [48,
49] which may, either directly or indirectly, lead to amyg-
dala atrophy. Intact connectivity of the frontostriatal circuits
is important in mood regulation [14, 50]. According to the
“vascular depression” hypothesis [14] SVD, that tends to
have a high prevalence in the frontostriatal regions, disrupts
fiber tracts within these circuits, probably leading to depres-
sive symptoms [11, 34].
There are two other studies that investigated the role of
amygdala morphometry in LODS patients. One [51] showed
that, despite insignificant amygdala volumetric findings,
variations of amygdala shape can be detected and localized.
They investigated so in 11 healthy elderly individuals and
14 depressed elderly individuals. A population-based cohort
study found a relation between a history of depression, parti-
cularly early onset, and an increased risk of for Alzheimer’s
disease; however this risk was not mediated by smaller
hippocampal or amygdala volumes at baseline [32]. In
contrast to our results they did not find a relation between
a history of depression or depressive symptoms at baseline
and smaller amygdala volume. As discussed earlier, this could
be because of the diﬀerence in degree of SVD between this
population-based cohort and our study sample in which we
included only subjects with some degree of SVD. As amyg-
dala volume is related to the degree of SVD [52], our study
sample will probably have smaller amygdalae. In addition
there was a diﬀerence in WML segmentation, most studies
used semiquantitative methods, and in contrast we manually
segmented the WML volume. This in combination with the
higher proportion of depressive symptoms in our study sam-
ple (42% versus 27%) can explain the relation we found
between amygdala volume and LODS in contrast to the find-
ings of this population-based cohort. Finally, the relation
between LODS and amygdala volume in our cohort was
mainly driven by the left amygdala, while this population-
based cohort summed both amygdalae in their analysis.
In conclusion, amygdala volume is associated with LODS,
independent of SVD and not with EODS. Future research
should consist of prospective studies in order to assess
whether baseline presence of SVD increases the risk of
amygdala atrophy at followup and whether this coincides
with LODS. Innovative MRI techniques including diﬀusion
tensor imaging (DTI) could oﬀer promising tools in order to
identify white matter tracts between the amygdala and other
parts of the brain and the eﬀects of SVD in those tracts with
respect to the incidence of LODS.
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